Cure MSA

Country specific patient information


Principal investigator:
Prof Tim Lynch, MB, BSc., DCH, FRCPI, FRCP, ABPN

Dublin Neurological Institute
57 Eccles Street,
Dublin 7,
T: +353 1 8545038/5258
F: +353 1 8545264
E: info(at)

Expertise of the participating organization:

The Dublin Neurological Institute (DNI) at the Mater Misericordiae University Hospital is Ireland’s first neurological institute and represents an innovative approach to combining the delivery of the high quality, holistic patient-centred care and an academic centre for research into neurological disorders and in particular neurodegenerative disorders such as dementia, Parkinson’s disease and atypical Parkinsonism.  The DNI is a non-profit organisation and strives to provide care for all patients with neurological disease irrespective of their health insurance status and its vision is to be a centre of excellence, providing multidisciplinary, innovative and compassionate care for all patients with neurological disorders in Ireland. 
The DNI is a referral centre for a wide variety of neurological disorders nationally and in the area of neurodegenerative disease is a tertiary referral centre with research interests including the basic science, genetics, clinical phenomenology and therapeutics of movement disorders and dementia.   
The Movement Disorder clinic at the DNI sees approximately 1500 patients per year including nurse led clinics.  Departmental data estimate that 59% of patients seen have idiopathic Parkinson’s disease (approximately 25% of which are young onset), 8.2% had atypical Parkinsonism (including  Multiple system atrophy and Progressive Supranuclear Palsy) and 5.8% had dystonia.  Further analysis estimates that 20% of referrals are for a tertiary or quaternary opinion.


Recent publications relevant to the EMSA-SG:

Lynch T, et al.  Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 1994;44:1878-1884.


Wilhelmsen KC, Lynch T, et el.  Localization of disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC) to 17q21-22. Am J Human Gen 1994;55: 1159-1165.


Hutton M, et al, Lynch T, Heutink P. Association of missense and 5’ splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393:702-705


Lynch T, et al. Genetics of Parkinson’s Disease. Science 1997; 278:1212-1213.


Lynch T, et al.  PCR-based detection of Tropheryma whippelli in CNS Whipple's disease. Ann Neurol 1997;42:120-124.


Vilarino-Guell, Lynch T et al. VPS35 mutations in Parkinson’s disease. Am J Hum Genet 2011;89:162-167


Vilarino-Guell C, Wider C, Aasly JO, White LR, Rajput A, Rajput AH, Lynch T, Krygowska-Wajs  A,  Jasinska-Myga B, Opala G, Barcikowska M, Czyzewski K, Wu R-M, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA. Association of Pyridoxal Kinase and Parkinson’s disease. Ann Neurol 2010; 67: 409-11


O’Rourke K, Kearney H, Murray B, Kavanagh E, Kelly P, Murphy P, Lynch T. Response to letter “Cerebral hyperperfusion syndrome remains underrecognised” J Neurol (in press)


O’Dowd S, Lynch T. Hot Topics: “Does secretion of aberrant tau underlie lesion spread in tauopathies.” Mov Disord 2012;27:201


Curtin D, Lynch T. Hot Topics: “New gene for ALS-FTD”. Mov Disorders 2012; 27:202


McKinley J, O'Connell M, Farrell M, Lynch T. Normal dopamine transporter imaging does not exclude multiple system atrophy. Parkinsonism Relat Disord 2014;20:933-934.